Cargando…

Cardiac Changes in Parkinson’s Disease: Lessons from Clinical and Experimental Evidence

Dysautonomia is a common non-motor symptom in Parkinson’s disease (PD). Most dysautonomic symptoms appear due to alterations in the peripheral nerves of the autonomic nervous system, including both the sympathetic and parasympathetic nervous systems. The degeneration of sympathetic nerve fibers and...

Descripción completa

Detalles Bibliográficos
Autores principales: Cuenca-Bermejo, Lorena, Almela, Pilar, Navarro-Zaragoza, Javier, Fernández Villalba, Emiliano, González-Cuello, Ana-María, Laorden, María-Luisa, Herrero, María-Trinidad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705692/
https://www.ncbi.nlm.nih.gov/pubmed/34948285
http://dx.doi.org/10.3390/ijms222413488
_version_ 1784622009572917248
author Cuenca-Bermejo, Lorena
Almela, Pilar
Navarro-Zaragoza, Javier
Fernández Villalba, Emiliano
González-Cuello, Ana-María
Laorden, María-Luisa
Herrero, María-Trinidad
author_facet Cuenca-Bermejo, Lorena
Almela, Pilar
Navarro-Zaragoza, Javier
Fernández Villalba, Emiliano
González-Cuello, Ana-María
Laorden, María-Luisa
Herrero, María-Trinidad
author_sort Cuenca-Bermejo, Lorena
collection PubMed
description Dysautonomia is a common non-motor symptom in Parkinson’s disease (PD). Most dysautonomic symptoms appear due to alterations in the peripheral nerves of the autonomic nervous system, including both the sympathetic and parasympathetic nervous systems. The degeneration of sympathetic nerve fibers and neurons leads to cardiovascular dysfunction, which is highly prevalent in PD patients. Cardiac alterations such as orthostatic hypotension, heart rate variability, modifications in cardiogram parameters and baroreflex dysfunction can appear in both the early and late stages of PD, worsening as the disease progresses. In PD patients it is generally found that parasympathetic activity is decreased, while sympathetic activity is increased. This situation gives rise to an imbalance of both tonicities which might, in turn, promote a higher risk of cardiac damage through tachycardia and vasoconstriction. Cardiovascular abnormalities can also appear as a side effect of PD treatment: L-DOPA can decrease blood pressure and aggravate orthostatic hypotension as a result of a negative inotropic effect on the heart. This unwanted side effect limits the therapeutic use of L-DOPA in geriatric patients with PD and can contribute to the number of hospital admissions. Therefore, it is essential to define the cardiac features related to PD for the monitorization of the heart condition in parkinsonian individuals. This information can allow the application of intervention strategies to improve the course of the disease and the proposition of new alternatives for its treatment to eliminate or reverse the motor and non-motor symptoms, especially in geriatric patients.
format Online
Article
Text
id pubmed-8705692
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87056922021-12-25 Cardiac Changes in Parkinson’s Disease: Lessons from Clinical and Experimental Evidence Cuenca-Bermejo, Lorena Almela, Pilar Navarro-Zaragoza, Javier Fernández Villalba, Emiliano González-Cuello, Ana-María Laorden, María-Luisa Herrero, María-Trinidad Int J Mol Sci Review Dysautonomia is a common non-motor symptom in Parkinson’s disease (PD). Most dysautonomic symptoms appear due to alterations in the peripheral nerves of the autonomic nervous system, including both the sympathetic and parasympathetic nervous systems. The degeneration of sympathetic nerve fibers and neurons leads to cardiovascular dysfunction, which is highly prevalent in PD patients. Cardiac alterations such as orthostatic hypotension, heart rate variability, modifications in cardiogram parameters and baroreflex dysfunction can appear in both the early and late stages of PD, worsening as the disease progresses. In PD patients it is generally found that parasympathetic activity is decreased, while sympathetic activity is increased. This situation gives rise to an imbalance of both tonicities which might, in turn, promote a higher risk of cardiac damage through tachycardia and vasoconstriction. Cardiovascular abnormalities can also appear as a side effect of PD treatment: L-DOPA can decrease blood pressure and aggravate orthostatic hypotension as a result of a negative inotropic effect on the heart. This unwanted side effect limits the therapeutic use of L-DOPA in geriatric patients with PD and can contribute to the number of hospital admissions. Therefore, it is essential to define the cardiac features related to PD for the monitorization of the heart condition in parkinsonian individuals. This information can allow the application of intervention strategies to improve the course of the disease and the proposition of new alternatives for its treatment to eliminate or reverse the motor and non-motor symptoms, especially in geriatric patients. MDPI 2021-12-16 /pmc/articles/PMC8705692/ /pubmed/34948285 http://dx.doi.org/10.3390/ijms222413488 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Cuenca-Bermejo, Lorena
Almela, Pilar
Navarro-Zaragoza, Javier
Fernández Villalba, Emiliano
González-Cuello, Ana-María
Laorden, María-Luisa
Herrero, María-Trinidad
Cardiac Changes in Parkinson’s Disease: Lessons from Clinical and Experimental Evidence
title Cardiac Changes in Parkinson’s Disease: Lessons from Clinical and Experimental Evidence
title_full Cardiac Changes in Parkinson’s Disease: Lessons from Clinical and Experimental Evidence
title_fullStr Cardiac Changes in Parkinson’s Disease: Lessons from Clinical and Experimental Evidence
title_full_unstemmed Cardiac Changes in Parkinson’s Disease: Lessons from Clinical and Experimental Evidence
title_short Cardiac Changes in Parkinson’s Disease: Lessons from Clinical and Experimental Evidence
title_sort cardiac changes in parkinson’s disease: lessons from clinical and experimental evidence
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705692/
https://www.ncbi.nlm.nih.gov/pubmed/34948285
http://dx.doi.org/10.3390/ijms222413488
work_keys_str_mv AT cuencabermejolorena cardiacchangesinparkinsonsdiseaselessonsfromclinicalandexperimentalevidence
AT almelapilar cardiacchangesinparkinsonsdiseaselessonsfromclinicalandexperimentalevidence
AT navarrozaragozajavier cardiacchangesinparkinsonsdiseaselessonsfromclinicalandexperimentalevidence
AT fernandezvillalbaemiliano cardiacchangesinparkinsonsdiseaselessonsfromclinicalandexperimentalevidence
AT gonzalezcuelloanamaria cardiacchangesinparkinsonsdiseaselessonsfromclinicalandexperimentalevidence
AT laordenmarialuisa cardiacchangesinparkinsonsdiseaselessonsfromclinicalandexperimentalevidence
AT herreromariatrinidad cardiacchangesinparkinsonsdiseaselessonsfromclinicalandexperimentalevidence